Related Experiment Videos
Summary
Orthoclone OKT3, a murine monoclonal antibody, effectively reverses acute transplant rejection, showing higher success rates than conventional treatments. Modifications improved safety and reduced antibody formation, establishing it as a valuable immunosuppressive therapy.
Area of Science:
- Immunology
- Transplantation Medicine
- Pharmacology
Background:
- Orthoclone OKT3 (murine monoclonal antibody) is used for acute transplant rejection.
- Early trials showed high efficacy but also limitations like first-dose reactions and antibody production.
Purpose of the Study:
- To evaluate the efficacy and safety of Orthoclone OKT3 in reversing acute rejection episodes.
- To assess improvements in OKT3 therapy and its long-term outcomes.
Main Methods:
- Randomized, multicenter clinical trials comparing OKT3 with conventional treatments.
- Modified therapeutic protocols to mitigate adverse reactions and antibody formation.
- Analysis of long-term allograft survival in patients treated with OKT3.
Main Results:
- OKT3 reversed 94% of acute rejection episodes versus 75% for conventional treatments.
- Modified OKT3 protocols reduced first-dose reactions and antibody production (86% to 39%).
- Long-term allograft survival of 75% achieved in patients treated with OKT3 and azathioprine-prednisone.
Conclusions:
- Orthoclone OKT3 is a safe and effective immunosuppressive therapy for transplant recipients.
- It offers higher specificity than traditional therapies like steroids or cytotoxic agents.
- OKT3 serves as a prototype for developing more targeted immunosuppressive protocols.